A Phase 3 interventional study of D745 formulation I and D745 formulation II in Type 2 Diabetes, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-12-10.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 3, Interventional, and Treatment
The purpose of this study is to prove that the group treated with D745 in combination added that the reduction of HbA1c superior to placebo treated group added in combination.
The aim of this phase 3 study is to evaluate the efficacy and safety of additional combined D745 administration for 24 weeks in patient with type 2 diabetes who are no adequately controlled for blood glucose by the combination of D150 and D759
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 172 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Chong Kun Dang Pharmaceutical is the lead sponsor of 293 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Pateints assigned to this group are treated with D150, D759 and D745 formulation I
Drug: D745 formulation I
Pateints assigned to this group are treated with D150, D759 and D745 formulation II
Drug: D745 formulation II
Pateints assigned to this group are treated with D150, D759 and D745 placebo
Drug: D745 Placebo
QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Change from baseline in HbA1c
Time frame: Baseline, 24 week
Change from baseline in HbA1c
Time frame: Baseline, 12 week
Change from baseline in Fasting plasma glucose
Time frame: Baseline, 12 week, 24 week
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chong Kun Dang Pharmaceutical